ZEAL.CO · PEAD → 0
Zealand Pharma reported Q3 2026 EPS of -10.02 DKK on 2026-11-12, beating the -10.91 consensus by 0.89 DKK (+8.2%); no prior-year comparable is available in the feed.
AI-generated — produced automatically by Closelooknet’s systems under this site’s editorial policy.
Zealand Pharma reported Q3 2026 EPS of -10.02 DKK on 2026-11-12, beating the -10.91 consensus by 0.89 DKK (+8.2%); no prior-year comparable is available in the feed.
Print-day reaction was -1.6% from the prior close, a modest negative response despite the EPS beat, with the stock settling at 241.1. The overnight gap to the T+1 open extended the decline by a further -1.3%, signalling no after-hours relief. Over the following two trading sessions the price drifted an additional -5.1%, deepening the loss with no meaningful recovery. With benchmark 3-day return data unavailable, CAR is uncomputable; per PEAD classification rules this resolves to a none verdict with zero conviction through the holding window ending 2027-02-09.
Names on this card
ZEAL.CO — chart, structure & Closelooknet read · AMGN — chart, structure & Closelooknet read